［1］Hanna JA, Bordeaux J, Rimm DL, et al. The function, proteolytic processing, and histopathology of Met in cancer［J］. Adv Cancer Res, 2009, 103: 1-23.
［2］Loyer X, Mallat Z, Boulanger CM, et al. MicroRNAs as therapeutic targets in atherosclerosis［J］. Expert Opin Ther Targets, 2015, 19(4): 489-496.
［3］Peng J, Qi S, Wang P, et al. Diagnosis and prognostic significance of c-met in cervical cancer: a meta-analysis［J］. Dis Markers, 2016, 2016: 6594016.
［4］Sun C, Liu Z, Li S, et al. Down-regulation of c-Met and Bcl2 by microRNA-206, activates apoptosis, and inhibits tumor cell proliferation, migration and colonyformation［J］. Oncotarget, 2015, 6(28): 25533-25574.
［5］Scagliotti GV, Novello S, von Pawel J. The emerging role of MET/HGF inhibitors in oncology［J］. Cancer Treat Rev, 2013, 39(7): 793-801.
［6］Gately K, Forde L, Cuffe S, et al. High coexpression of both EGFR and IGF1R correlates with poor patient prognosis in resected non-small-cell lung cancer［J］. Clin Lung Cancer, 2014, 15(1): 58-66.
［7］Maroun CR, Rowlands T. The Met receptor tyrosine kinase: a key player in oncogenesis and drug resistance［J］. Pharmacol Ther, 2014, 142(3): 316-338.
［8］Sadiq AA, Salgia R. MET as a possible target for non-small-cell lung cancer［J］. J Clin Oncol, 2013, 31(8): 1089-1096.
［9］Cipriani NA, Abidoye OO, Vokes E, et al. MET as a target for treatment of chest tumors［J］. Lung Cancer, 2009, 63(2): 169-179.
［10］Taulli R, Bersani F, Foglizzo V, et al. The muscle-specific microRNA miR-206 blocks human rhabdomyosarcoma growth in xenotransplanted mice by promoting myogenic differentiation［J］. J Clin Invest, 2009, 119(8): 2366-2378.
［11］Kefas B, Godlewski J, Comeau L, et al. microRNA-7 inhibits the epidermal growth factor receptor and the Akt pathway and is down-regulated in glioblastoma［J］. Cancer Res, 2008, 68(10): 3566-3572.
［12］Li Y, Vandenboom TG II, Wang Z, et al. miR-146a suppresses invasion of pancreatic cancer cells［J］. Cancer Res, 2010, 70(4): 1486-1495.
［13］Mataki H, Seki N, Chiyomaru T, et al. Tumor-suppressive microRNA-206 as a dual inhibitor of MET and EGFR oncogenic signaling in lung squamous cell carcinoma［J］. Int J Oncol, 2015, 46(3): 1039-1050.
［14］Zheng Z, Yan D, Chen X, et al. MicroRNA-206: effective inhibition of gastric cancer progression through the c-met pathway［J］. PLoS One. 2015, 10(7): e0128751.
［15］Luan S, Sun L, Huang F. MicroRNA-34a: a novel tumor suppressor in p53-mutant glioma cell line U251［J］. Arch Med Res, 2010, 41(2): 67-74.
［16］Guessous F, Zhang Y, Kofman A, et al. MicroRNA-34a is tumor suppressive in brain tumors and glioma stem cells［J］. Cell Cycle, 2010, 9(6): 1031-1036.
［17］Zauli G, Voltan R, di Iasio MG, et al. miR-34a induces the downregulation of both E2F1 and B-Myb oncogenes in leukemic cells［J］. Clin Cancer Res, 2011, 17(9): 2712-2724.
［18］Siemens H, Jackstadt R, Hünten S, et al. miR-34 and SNAIL form a double-negative feedback loop to regulate epithelial-mesenchymal transitions［J］. Cell Cycle, 2011, 10(24): 4256-4271.
［19］Liu YW, Sun M, Xia R, et al. LincHOTAIR epigenetically silences miR34a by binding to PRC2 to promote the epithelial-to-mesenchymal transition in human gastric cancer［J］. Cell Death Dis, 2015, 6: e1802.
［20］Wang Y, Shi J, Chai K, et al. The role of snail in EMT and tumorigenesis［J］. Curr Cancer Drug Targets, 2013, 13(9): 963-972.
［21］Liu WT, Jing YY, Yu GF, et al. Hepatic stellate cell promoted hepatoma cell invasion via the HGF/c-Met signaling pathway regulated by p53［J］. Cell Cycle, 2016, 15(7): 886-894.
［22］Hong JH, Roh KS, Suh SS, et al. The expression of microRNA-34a is inversely correlated with c-MET and CDK6 and has a prognostic significance in lung adenocarcinoma patients［J］. Tumour Biol, 2015, 36(12): 9327-9337.
［23］Li C, Wang Y, Lu S, et al. MiR-34a inhibits colon cancer proliferation and metastasis by inhibiting platelet-derived growth factor receptor α［J］. Mol Med Rep, 2015, 12(5): 7072-7078.
［24］Sanchez I, Dynlacht BD. Cell biology: short RNAs and shortness of breath［J］. Nature, 2014, 510(7503): 40-42.
［25］Sun L, Bian G, Meng Z, et al. MiR-144 inhibits uveal melanoma cell proliferation and invasion by regulating c-met expression［J］. PLoS One, 2015, 10(5): e0124428.
［26］Zhang LY, Ho-Fun Lee V, Wong AM, et al. MicroRNA-144 promotes cell proliferation, migration and invasion in nasopharyngeal carcinoma through repression of PTEN［J］. Carcinogenesis, 2013, 34(2): 454-463.
［27］Alam R, Schultz CR, Golembieski WA, et al. PTEN suppresses SPARC-induced pMAPKAPK2 and inhibits SPARC-induced Ser78 HSP27 phosphorylation in glioma［J］. Neuro Oncol, 2013, 15(4): 451-461.
［28］Lan F, Yu H, Hu M, et al. miR-144-3P exerts anti-tumor effects in glioblastoma by targeting c-met［J］. J Neurochem, 2015, 135(2): 274-286.
［29］Yang YM, Lee CG1, Koo JH, et al. Ga12 overexpressed in hepatocellular carcinoma reduces microRNA-122 expression via HNF4a inactivation, which causes c-Met induction［J］. Oncotarget, 2015, 6(22): 19055-19069.
［30］Li ZY, Xi Y, Zhu WN, et al. Positive regulation of hepatic miR-122 expression by HNF4α［J］. J Hepatol, 2011, 55(3): 602-611.
［31］Liu X, Jiang L, Wang A, et al. MicroRNA-138 suppresses invasion and promotes apoptosis in head and neck squamous cell carcinoma cell lines［J］. Cancer Lett, 2009, 286(2): 217-222.
［32］Yeh YM, Chuang CM, Chao KC, et al. MicroRNA-138 suppresses ovarian cancer cell invasion and metastasis by targeting sOX4 and HIF-1α［J］. Int J Cancer, 2013, 133(4): 867-878.
［33］Seike M, Goto A, Okano T, et al. MiR-21 is an eGFR-regulated anti-apoptotic factor in lung cancer in never-smokers［J］. Proc Natl Acad Sci U S A, 2009, 106(29): 12085-12090.
［34］Li B, Yang XX, Wang D, et al. MicroRNA-138 inhibits proliferation of cervical cancer cells by targeting c-Met［J］. Eur Rev Med Pharmacol Sci, 2016, 20(6): 1109-1114.
［35］Zhuang HQ, Bo QF, Yuan ZY, et al. The different radiosensitivity when combining erlotinib with radiation at different administration schedules might be related to activity variations in c-MeT-PI3K-AKT signal transduction［J］. Onco Targets Ther, 2013, 6: 603-608.
［36］Liu Y, Yang Y, Ye YC, et al. Activation of eRK-p53 and eRK-mediated phosphorylation of Bcl-2 are involved in autophagic cell death induced by the c-Met inhibitor sU11274 in human lung cancer A549 cells［J］. J Pharmacol Sci, 2012,118(4): 423-432.
［37］Shang N, Arteaga M, Zaidi A, et al. FAK is required for c-Met/beta-catenin-driven hepatocarcinogenesis［J］. Hepatology, 2015, 61(1): 214-226.
［38］Zhen Q, Liu J, Gao L, et al. MicroRNA-200a targets EGFR and c-met to inhibit migration, invasion, and gefitinib resistance in non-small cell lung cancer［J］. Cytogenet Genome Res, 2015, 146(1): 1-8.
［39］Ohta K, Hoshino H, Wang J, et al. MicroRNA-93 activates c-Met/PI3K/Akt pathway activity in hepatocellular carcinoma by directly inhibiting PTEN and CDKN1A［J］. Oncotarget, 2015, 6(5): 3211-3224.
［40］Huang J, Dong B, Zhang J, et al. miR-199a-3p inhibits hepatocyte growth factor/c-Met signaling in renal cancer carcinoma［J］. Tumour Biol, 2014, 35(6): 5833-5843.
［41］Kinose Y, Sawada K, Nakamura K, et al. The hypoxia-related microRNA miR-199a-3p displays tumor suppressor functions in ovarian carcinoma［J］. Oncotarget, 2015, 6(13): 11342-11356.
［42］Wu J, Ji A, Wang X, et al. MicroRNA-195-5p, a new regulator of Fra-1, suppresses the migration and invasion of prostate cancer cells［J］. J Transl Med, 2015, 13(1): 1-15.
［43］Gao Y, Zeng F, Wu JY, et al. MiR-335 inhibits migration of breast cancer cells through targeting oncoprotein c-Met［J］. Tumour Biol, 2015, 36(4): 2875-2883.
［44］Wan L, Zhu L, Xu J, et al. MicroRNA-409-3p functions as a tumor suppressor in human lung adenocarcinoma by targeting c-Met［J］. Cell Physiol Biochem, 2014, 34(4): 1273-1290.
［45］Niu G, Li B, Sun J, et al. miR-454 is down-regulated in osteosarcomas and suppresses cell proliferation and invasion by directly targeting c-Met［J］. Cell Prolif, 2015, 48(3): 348-355. 
［46］Zhang Y, Wang Z, Chen M, et al. MicroRNA-143 targets MACC1 to inhibit cell invasion and migration in colorectal cancer［J］. Mol Cancer, 2012, 11(1): 1-9.
［47］Huang N, Wu Z, Lin L, et al. MiR-338-3p inhibits epithelial-mesenchymal transition in gastric cancer cells by targeting ZEB2 and MACC1/Met/Akt signaling［J］. Oncotarget, 2015, 6(17): 15222-15234.
［48］Dong N, Tang X, Xu B. miRNA-181a inhibits the proliferation, migration, and epithelial-mesenchymal transition of lens epithelial cells［J］. Invest Ophthalmol Vis Sci, 2015, 56(2): 993-1001.
［49］Xu J, Huang Z, Lin L, et al. miR-210 over-expression enhances mesenchymal stem cell survival in an oxidative stress environment through antioxidation and c-Met pathway activation［J］. Sci China Life Sci, 2014, 57(10): 989-997.